Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet

Jan 17 2012

• By Paul Bonanos

Related Content

Abbott Adds Epigenetics To Its Anticancer R&D Through EpiTherapeutics Deal

Dec 20 2010

Seeking Drugs “Hidden In Microbes,” Third Rock Launches Warp Drive Bio

Jan 10 2012

Cancer Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Nov 07 2011

Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy

Jun 27 2011

Eisai Deal Puts Epizyme In Position To Advance Lead Program

Mar 10 2011

GSK Teams Up With EpiZyme To Develop Epigenetic Drugs

Jan 10 2011

Constellation Brings In Series B Totaling $22 Million, Including GSK Investment

Jun 02 2010

The Epigenetics (R)evolution

Mar 01 2009

Related Companies

Genentech, Inc.

Constellation Pharmaceuticals, Inc.

GSK plc

Epizyme, Inc.

Warp Drive Bio, Inc.

Sanofi

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Forma Therapeutics Inc.

Abbott

Gilead Sciences, Inc.

Additional Topics

United States Deals BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window